2022 年中国女性乳腺癌的发病率、死亡率和伤残调整生命年。

Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.

机构信息

Office of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

出版信息

Chin Med J (Engl). 2024 Oct 20;137(20):2429-2436. doi: 10.1097/CM9.0000000000003278. Epub 2024 Sep 5.

DOI:10.1097/CM9.0000000000003278

PMID:39238088

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11479498/

Abstract

BACKGROUND

Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.

METHODS

In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).

RESULTS

In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.

CONCLUSION

These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.

摘要

背景

乳腺癌在中国女性人群中的发病率位居最常见恶性肿瘤之列。然而，有关最新流行病学数据和可归因疾病负担的综合报告尚未广泛记录。

方法

2018 年，中国 700 个基于人群的癌症监测点记录了高质量的癌症监测数据。我们根据 2010 年至 2018 年的基线数据和相应趋势，提取了女性乳腺癌（国际疾病分类，第十版 [ICD-10]：C50）的数据，并估计了 2022 年的发病率和死亡率。病理类型按照国际肿瘤学分类，第 3 版（ICD-O-3）代码进行分类。伤残调整生命年（DALYs）计算为生命损失年（YLLs）和伤残生存年（YLDs）的总和。

结果

2022 年，中国约有 35.72 万例新发女性乳腺癌病例和 7.5 万例死亡病例，分别占新发癌症病例和死亡病例总数的 15.59%和 7.94%。年龄标准化发病率（ASIR）为 33.04/10 万。按病理类型分析，乳头状肿瘤、浸润性乳腺癌、罕见和唾液腺型肿瘤以及其他类型的 ASIR 分别为 1.13/10 万、29.79/10 万、0.24/10 万和 1.88/10 万。年龄标准化死亡率（ASMR）为 6.10/10 万。在中国，归因于女性乳腺癌的 DALYs 总计为 262.8 万，其中 YLLs 为 227.83 万，YLDs 为 34.97 万。城市地区的 ASIR、ASMR 和年龄标准化率（ASR）均高于农村地区。与 55 岁以下女性相比，55 岁以上女性的 DALY 的 ASIR、ASR 增加了 4 倍，ASMR 增加了 8 倍。